Abstract: The present disclosure relates to methods of treating a tumor with a nucleotide vaccine (e.g., DNA vaccine encoding a tumor antigen) in combination with an IL-7. In some aspects, the IL-7 is administered after the administration of the nucleotide vaccine (e.g., after the peak expansion phase of the tumor-specific T cell immune response) or concurrently with the nucleotide vaccine.

Abstract: The present disclosure is directed to compositions and methods of treating Triple Negative Breast Cancer (TNBC) in a human subject. A method of treating TNBC in a human subject includes administering a therapeutically effective amount of a neoantigen vaccine composition comprising a fusion protein comprising at least one TNBC-associated neoantigen epitope joined to a mutant ubiquitin protein, or a nucleic acid molecule encoding such a protein.

Abstract: An isolated antigenic peptide fragment that is an isolated oncogene protein fragment is disclosed. The isolated peptide fragment of the invention is a peptide either 9 or 10 amino acid residues in length that includes at least a leucine residue at the C- terminus (i.e., position 9 or position 10). The peptide fragment is capable of binding in an HLA-A2 binding cleft and is capable of stimulating proliferation of at least one tumor-specific cytotoxic T-lymphocyte. Preferred peptides further include an isoleucine residue at position 2 and a valine residue at position 6. The most preferred isolated peptides can stimulate proliferation of cytotoxic T-lymphocytes obtainable from peripheral blood lymphocytes, ovarian tumors, breast tumors, gastric tumors, non-small cell lung tumors, pancreatic tumors, colon tumors, gliomas, bladder tumors, endometrial tumors and neuroblastomas. The preferred isolated peptide of the invention is a mutant peptide defined by SEQ ID NO.:2 or its functional equivalents.